language-icon Old Web
English
Sign In
Acemap > Field > Daclizumab HYP

Daclizumab HYP

[ "IL-2 receptor", "Multiple sclerosis", "relapse rate", "Daclizumab", "disability progression" ]
Parent Topic
Child Topic
    No Parent Topic
logo
  • CCF Conference Analysis
  • Map Galaxy
  • What's New
© Copyright 2015-2020 Acemap, Inc. Shanghai Jiao Tong University.